← Leaderboards
Blossom A Damania
University Of North Carolina Chapel Hill
$35,988,246
Attributed
$44,859,239
Total exposure
33
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$81,037,747 · 36
By mechanism
P01$31,431,742 · 8
R01$26,398,276 · 9
U54$15,806,171 · 11
U19$4,346,526 · 2
U01$1,290,024 · 1
RC2$997,466 · 1
Top collaborators
- Dirk P Dittmer40 shared
- Sam Jp Phiri36 shared
- Satish Gopal35 shared
- Nancy Joan Raab-Traub17 shared
- Yuri Fedoriw8 shared
- Carla J Chibwesha7 shared
- Paul Ruff7 shared
- Jacqueline Huwa4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Shannon Celeste Kenney$30,359,662
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsKaposi SarcomaHuman Herpesvirus 8LymphomaCellsTumorViralMediatingPathway InteractionsProteinsReportingAfrica South Of The SaharaVirusViral ProteinsSignal TransductionGene ExpressionResponseAcquired Immunodeficiency SyndromeIn VivoAffectFundingSignal PathwayProgramsHerpesviridae
Grant awards (196)
Viral Oncogenesis, Latency, and Replication$1,936,921
P01 · FY2025 · CA · contact PI
Targeting EBV-associated lymphomas$645,012
U01 · FY2025 · CA · contact PI
Therapy for Non-Hodgkin lympoma$435,930
R01 · FY2025 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,139
R01 · FY2025 · CA
Gammaherpesviral interactions with the host cell$347,154
P01 · FY2025 · CA · contact PI
Administrative Core A$145,686
P01 · FY2025 · CA · contact PI
Viral Oncogenesis, Latency, and Replication$1,936,921
P01 · FY2024 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,094,228
U54 · FY2024 · CA · contact PI
Targeting EBV-associated lymphomas$645,012
U01 · FY2024 · CA · contact PI
Therapy for Non-Hodgkin lympoma$435,506
R01 · FY2024 · CA · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,103
R01 · FY2024 · CA
Gammaherpesviral interactions with the host cell$347,154
P01 · FY2024 · CA · contact PI
Administrative Core$236,677
U54 · FY2024 · CA · contact PI
Administrative Core A$145,686
P01 · FY2024 · CA · contact PI
Viral Oncogenesis, Latency, and Replication$1,936,921
P01 · FY2023 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,097,066
U54 · FY2023 · CA · contact PI
Mechanisms of KSHV Transmission$583,738
R01 · FY2023 · CA
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,103
R01 · FY2023 · CA
Gammaherpesviral interactions with the host cell$347,154
P01 · FY2023 · CA · contact PI
Administrative Core$236,678
U54 · FY2023 · CA · contact PI
Supplement: The Association Between Stigma and Wellbeing among Kaposi sarcoma and Lymphoma Patients in Malawi$172,245
U54 · FY2023 · CA · contact PI
Administrative Core$172,245
U54 · FY2023 · CA · contact PI
Administrative Core A$145,686
P01 · FY2023 · CA · contact PI
Viral Oncogenesis, Latency, and Replication$1,936,921
P01 · FY2022 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,101,859
U54 · FY2022 · CA · contact PI
Mechanisms of KSHV Transmission$583,738
R01 · FY2022 · CA
Modulation of Innate Immunity by KSHV$412,880
R01 · FY2022 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$400,137
R01 · FY2022 · CA
Impact of HIV on the Tumor Microenvironment$387,192
R01 · FY2022 · CA
Gammaherpesviral interactions with the host cell$347,154
P01 · FY2022 · CA · contact PI
Role of KSHV Viral Proteins in Signaling and Pathogenesis$314,888
R01 · FY2022 · CA · contact PI
Administrative Core$239,904
U54 · FY2022 · CA · contact PI
Administrative Core A$145,686
P01 · FY2022 · CA · contact PI
Performance of different sample types for high-risk human papillomavirus testing and genotyping for the detection of high grade cervical intraepithelial neoplasia$125,000
U54 · FY2022 · CA · contact PI
Administrative Core$125,000
U54 · FY2022 · CA · contact PI
Role of KSHV Viral Proteins in Signaling and Pathogenesis$72,294
R01 · FY2022 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,109,032
U54 · FY2021 · CA · contact PI
Mechanisms of KSHV Transmission$583,738
R01 · FY2021 · CA
Modulation of Innate Immunity by KSHV$420,266
R01 · FY2021 · DE · contact PI
Impact of HIV on the Tumor Microenvironment$387,192
R01 · FY2021 · CA
Role of KSHV Viral Proteins in Signaling and Pathogenesis$314,888
R01 · FY2021 · CA · contact PI
Administrative Core$242,001
U54 · FY2021 · CA · contact PI
The road to recovery: An assessment of patient-reported quality of life among cancer survivors in Malawi.$190,625
U54 · FY2021 · CA · contact PI
Administrative Core$190,625
U54 · FY2021 · CA · contact PI
Role of KSHV Viral Proteins in Signaling and Pathogenesis$72,294
R01 · FY2021 · CA · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$1,812,045
P01 · FY2020 · CA · contact PI
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,180,460
U54 · FY2020 · CA · contact PI
Mechanisms of KSHV Transmission$550,989
R01 · FY2020 · CA
Modulation of Innate Immunity by KSHV$427,505
R01 · FY2020 · DE · contact PI
Impact of HIV on the Tumor Microenvironment$387,192
R01 · FY2020 · CA
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2020 · CA
Role of KSHV Viral Proteins in Signaling and Pathogenesis$314,888
R01 · FY2020 · CA · contact PI
Project 3 - Modulation of host cell biology by KSHV$280,067
P01 · FY2020 · CA · contact PI
Administrative Core$255,876
U54 · FY2020 · CA · contact PI
Core A - Administration$162,068
P01 · FY2020 · CA · contact PI
Role of KSHV Viral Proteins in Signaling and Pathogenesis$72,294
R01 · FY2020 · CA · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$1,757,717
P01 · FY2019 · CA · contact PI
Mechanisms of KSHV Transmission$527,310
R01 · FY2019 · CA
Modulation of Innate Immunity by KSHV$434,473
R01 · FY2019 · DE · contact PI
Impact of HIV on the Tumor Microenvironment$375,575
R01 · FY2019 · CA
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2019 · CA
Role of KSHV Viral Proteins in Signaling and Pathogenesis$305,441
R01 · FY2019 · CA · contact PI
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu$298,262
U54 · FY2019 · CA
Project 3 - Modulation of host cell biology by KSHV$272,323
P01 · FY2019 · CA · contact PI
Core A - Administration$154,302
P01 · FY2019 · CA · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$63,936
P01 · FY2019 · CA · contact PI
Core A - Administration$9,134
P01 · FY2019 · CA · contact PI
Project 3 - Modulation of host cell biology by KSHV$9,134
P01 · FY2019 · CA · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$1,812,080
P01 · FY2018 · CA · contact PI
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu$745,654
U54 · FY2018 · CA · contact PI
Impact of HIV on the Tumor Microenvironment$466,495
R01 · FY2018 · CA
Modulation of Innate Immunity by KSHV$441,375
R01 · FY2018 · DE · contact PI
Innate Recognition of Human Herpesviruses$415,943
U19 · FY2018 · AI · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2018 · CA
Role of KSHV Viral Proteins in Signaling and Pathogenesis$314,888
R01 · FY2018 · CA · contact PI
Project 3 - Modulation of host cell biology by KSHV$280,088
P01 · FY2018 · CA · contact PI
Project 2$219,613
U54 · FY2018 · CA
Project 3$169,666
U54 · FY2018 · CA
Core A - Administration$162,069
P01 · FY2018 · CA · contact PI
Admin$145,813
U54 · FY2018 · CA
Mentoring$106,324
U54 · FY2018 · CA
Herpesviral Oncogenesis, Latency and Reactivation$63,936
P01 · FY2018 · CA · contact PI
Project 1$55,260
U54 · FY2018 · CA
Analytics$48,978
U54 · FY2018 · CA
Project 3 - Modulation of host cell biology by KSHV$9,134
P01 · FY2018 · CA · contact PI
Core A - Administration$9,134
P01 · FY2018 · CA · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$1,812,080
P01 · FY2017 · CA · contact PI
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu$875,813
U54 · FY2017 · CA
Study of Novel HHV8/KSHV Encoded Genes$553,506
U19 · FY2017 · AI · contact PI
Innate Recognition of Human Herpesviruses$415,379
U19 · FY2017 · AI · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$394,639
R01 · FY2017 · DE · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2017 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2017 · CA
Project 3 - Modulation of host cell biology by KSHV$301,307
P01 · FY2017 · CA · contact PI
Role of KSHV viral proteins in signaling and pathogenesis$281,108
R01 · FY2017 · CA · contact PI
Project 2$251,154
U54 · FY2017 · CA
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$236,852
R01 · FY2017 · CA
Project 3$198,456
U54 · FY2017 · CA
Admin$168,313
U54 · FY2017 · CA
Mentoring$143,550
U54 · FY2017 · CA
Core A - Administration$65,270
P01 · FY2017 · CA · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$63,936
P01 · FY2017 · CA · contact PI
Project 1$62,181
U54 · FY2017 · CA
Analytics$52,159
U54 · FY2017 · CA
2017 Viruses and Cells Gordon Research Conference and Gordon Research Seminar$7,500
R13 · FY2017 · AI · contact PI
Herpesviral Oncogenesis, Latency and Reactivation$1,811,800
P01 · FY2016 · CA · contact PI
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu$749,897
U54 · FY2016 · CA
Innate Recognition of Human Herpesviruses$415,378
U19 · FY2016 · AI · contact PI
Study of Novel HHV8/KSHV Encoded Genes$401,898
U19 · FY2016 · AI · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2016 · DE · contact PI
Innate Immunity and KSHV$365,968
R01 · FY2016 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$342,759
R01 · FY2016 · CA
Project 3 - Modulation of host cell biology by KSHV$308,968
P01 · FY2016 · CA · contact PI
Role of KSHV viral proteins in signaling and pathogenesis$281,108
R01 · FY2016 · CA · contact PI
Project 2$214,825
U54 · FY2016 · CA
Project 3$170,200
U54 · FY2016 · CA
Admin$144,000
U54 · FY2016 · CA
Mentoring$122,777
U54 · FY2016 · CA
Core A - Administration$65,286
P01 · FY2016 · CA · contact PI
Project 1$53,449
U54 · FY2016 · CA
Analytics$44,646
U54 · FY2016 · CA
Herpesviral, Oncogenesis, Latency and Reactivation$1,832,044
P01 · FY2015 · CA
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu$749,896
U54 · FY2015 · CA
Study of Novel HHV8/KSHV Encoded Genes$421,563
U19 · FY2015 · AI · contact PI
Innate Recognition of Human Herpesviruses$415,872
U19 · FY2015 · AI · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2015 · DE · contact PI
Innate Immunity and KSHV$365,968
R01 · FY2015 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$305,754
R01 · FY2015 · CA
Modulation of Cell Migration, Survival and Angiogenesis by KSHV$291,379
P01 · FY2015 · CA · contact PI
Role of KSHV viral proteins in signaling and pathogenesis$281,108
R01 · FY2015 · CA · contact PI
Project 2$251,630
U54 · FY2015 · CA
Project 3$153,730
U54 · FY2015 · CA
Admin$135,630
U54 · FY2015 · CA
Mentoring$113,518
U54 · FY2015 · CA
Project 1$52,812
U54 · FY2015 · CA
Analytics$42,576
U54 · FY2015 · CA
Herpesviral, Oncogenesis, Latency and Reactivation$1,777,079
P01 · FY2014 · CA
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu$747,934
U54 · FY2014 · CA
Study of Novel HHV8/KSHV Encoded Genes$473,768
U19 · FY2014 · AI · contact PI
Innate Recognition of Human Herpesviruses$415,378
U19 · FY2014 · AI · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2014 · DE · contact PI
Innate Immunity and KSHV$365,968
R01 · FY2014 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$296,581
R01 · FY2014 · CA
Modulation of Cell Migration, Survival and Angiogenesis by KSHV$283,526
P01 · FY2014 · CA · contact PI
Role of KSHV viral proteins in signaling and pathogenesis$272,674
R01 · FY2014 · CA · contact PI
Pathobiology and Clinical Profile of HIV-Associated Cancers in India and the West$204,706
R21 · FY2014 · CA
Project 2$189,417
U54 · FY2014 · CA
Project 3$164,099
U54 · FY2014 · CA
Admin$149,600
U54 · FY2014 · CA
Mentoring$109,282
U54 · FY2014 · CA
Project 1$80,957
U54 · FY2014 · CA
Analytics$54,579
U54 · FY2014 · CA
Herpesviral, Oncogenesis, Latency and Reactivation$1,722,119
P01 · FY2013 · CA
Study of Novel HHV8/KSHV Encoded Genes$417,841
U19 · FY2013 · AI · contact PI
Targeting the epigenome of gammaherpesviruses in oral disease$378,255
R01 · FY2013 · DE · contact PI
Innate Immunity and KSHV$351,329
R01 · FY2013 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$287,409
R01 · FY2013 · CA
Role of KSHV viral proteins in signaling and pathogenesis$281,108
R01 · FY2013 · CA · contact PI
Modulation of Cell Migration, Survival and Angiogenesis by KSHV$273,897
P01 · FY2013 · CA · contact PI
Pathobiology and Clinical Profile of HIV-Associated Cancers in India and the West$206,901
R21 · FY2013 · CA
Herpesviral, Oncogenesis, Latency and Reactivation$1,832,043
P01 · FY2012 · CA
Innate Immunity and KSHV$365,968
R01 · FY2012 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$305,754
R01 · FY2012 · CA
Modulation of Cell Migration, Survival and Angiogenesis by KSHV$291,380
P01 · FY2012 · CA · contact PI
Herpesviral, Oncogenesis, Latency and Reactivation$1,832,038
P01 · FY2011 · CA
Innate Immunity and KSHV$318,247
R01 · FY2011 · DE · contact PI
Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma$305,754
R01 · FY2011 · CA
Modulation of Cell Migration, Survival and Angiogenesis by KSHV$291,379
P01 · FY2011 · CA · contact PI
Role of KSHV K1 in viral pathogenesis$271,364
R01 · FY2011 · CA · contact PI
Development of a novel vaccine for protection against gammaherpesvirus infection$499,659
RC2 · FY2010 · CA · contact PI
Innate Immunity and KSHV$328,089
R01 · FY2010 · DE · contact PI
Role of KSHV K1 in viral pathogenesis$279,757
R01 · FY2010 · CA · contact PI
DEVELOPMENT OF A NOVEL VACCINE FOR PROTECTION AGAINST GAMMA HERPESVIRUS$202,435
P51 · FY2010 · RR · contact PI
Development of a novel vaccine for protection against gammaherpesvirus infection$497,807
RC2 · FY2009 · CA · contact PI
Viral Infection and Primary Pulmonary Hypertension$344,622
R01 · FY2009 · HL · contact PI
Innate Immunity and KSHV$331,404
R01 · FY2009 · DE · contact PI
Role of KSHV K1 in viral pathogenesis$279,757
R01 · FY2009 · CA · contact PI
Viral Infection and Primary Pulmonary Hypertension$344,622
R01 · FY2008 · HL · contact PI
Innate Immunity and KSHV$331,404
R01 · FY2008 · DE · contact PI
Role of KSHV K1 in viral pathogenesis$279,757
R01 · FY2008 · CA · contact PI
Viral Infection and Primary Pulmonary Hypertension$344,622
R01 · FY2007 · HL · contact PI
Innate Immunity and KSHV$335,090
R01 · FY2007 · DE · contact PI
Role of KSHV K1 in viral pathogenesis$257,632
R01 · FY2007 · CA · contact PI
Viral Infection and Primary Pulmonary Hypertension$354,915
R01 · FY2006 · HL · contact PI
Role of KSHV K1 and RRV R1 in viral pathogenesis$251,728
R01 · FY2006 · CA · contact PI
Role of KSHV K1 and RRV R1 in viral pathogenesis$39,480
R01 · FY2006 · CA · contact PI
Viral Infection and Primary Pulmonary Hypertension$363,456
R01 · FY2005 · HL
Role of KSHV K1 and RRV R1 in viral pathogenesis$257,786
R01 · FY2005 · CA
Genetic system for thesus monkey rhadinovirus (RRV)$73,000
R03 · FY2005 · AI
Role of KSHV K1 and RRV R1 in viral pathogenesis$39,480
R01 · FY2005 · CA
Role of KSHV K1 and RRV R1 in viral pathogenesis$276,961
R01 · FY2004 · CA
Genetic system for Rhesus monkey rhadinovirus (RRV)$73,000
R03 · FY2004 · AI
Role of KSHV K1 and RRV R1 in viral pathogenesis$39,480
R01 · FY2004 · CA
Role of KSHV K1 and RRV R1 in viral pathogenesis$257,786
R01 · FY2003 · CA
Role of KSHV K1 and RRV R1 in viral pathogenesis$39,480
R01 · FY2003 · CA
Role of KSHV K1 and RRV R1 in viral pathogenesis$257,786
R01 · FY2002 · CA